Active	Status	Sponsor type	Region	Phase	Filter
4 Active 0 Inactive 4 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes: « July » « 2025 » M T W T F S S 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1 2 3   - « July » « 2025 » M T W T F S S 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1 2 3   Show only changed items Enrollment:

Advanced Filters

4 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Daria, Diane
NAVIGATE, NCT04365868 / 2019-001983-31: Study Evaluating the Efficacy and Safety of Belapectin for the Prevention of Esophageal Varices in NASH Cirrhosis	Active, not recruiting	2/3	357	Europe, Canada, US, RoW	belapectin, GR-MD-02, galactoarabino rhamnogalacturonate, Placebo	Galectin Therapeutics Inc., Galectin Therapeutics Inc	Prevention of Esophageal Varices, NASH - Nonalcoholic Steatohepatitis, Cirrhosis	03/25	09/25
SARO.20.002, NCT05011305: Saroglitazar Magnesium for the Treatment of Nonalcoholic Steatohepatitis with Fibrosis	Active, not recruiting	2	180	US, RoW	Saroglitazar Magnesium 2 mg, Investigational Product, Saroglitazar Magnesium 4 mg, Placebo, Comparator Agent	Zydus Therapeutics Inc.	Nonalcoholic Steatohepatitis, Fibrosis	09/25	09/25
Jones, Ann
SARO.20.002, NCT05011305: Saroglitazar Magnesium for the Treatment of Nonalcoholic Steatohepatitis with Fibrosis	Active, not recruiting	2	180	US, RoW	Saroglitazar Magnesium 2 mg, Investigational Product, Saroglitazar Magnesium 4 mg, Placebo, Comparator Agent	Zydus Therapeutics Inc.	Nonalcoholic Steatohepatitis, Fibrosis	09/25	09/25
ALTUS, NCT05064553: Performance of a Multi- Target Hepatocellular Carcinoma (HCC) Test in Subjects With Increased Risk	Recruiting	N/A	2500	US	Study CT/MRI Imaging, Standard of Care CT/MRI Imaging, Oncoguard™ Liver Test	Exact Sciences Corporation	Hepatocellular Carcinoma, Hepatocellular Cancer, Hepatitis B, Cirrhosis, Liver Cancer	06/25	12/26

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Daria, Diane
NAVIGATE, NCT04365868 / 2019-001983-31: Study Evaluating the Efficacy and Safety of Belapectin for the Prevention of Esophageal Varices in NASH Cirrhosis	Active, not recruiting	2/3	357	Europe, Canada, US, RoW	belapectin, GR-MD-02, galactoarabino rhamnogalacturonate, Placebo	Galectin Therapeutics Inc., Galectin Therapeutics Inc	Prevention of Esophageal Varices, NASH - Nonalcoholic Steatohepatitis, Cirrhosis	03/25	09/25
SARO.20.002, NCT05011305: Saroglitazar Magnesium for the Treatment of Nonalcoholic Steatohepatitis with Fibrosis	Active, not recruiting	2	180	US, RoW	Saroglitazar Magnesium 2 mg, Investigational Product, Saroglitazar Magnesium 4 mg, Placebo, Comparator Agent	Zydus Therapeutics Inc.	Nonalcoholic Steatohepatitis, Fibrosis	09/25	09/25
Jones, Ann
SARO.20.002, NCT05011305: Saroglitazar Magnesium for the Treatment of Nonalcoholic Steatohepatitis with Fibrosis	Active, not recruiting	2	180	US, RoW	Saroglitazar Magnesium 2 mg, Investigational Product, Saroglitazar Magnesium 4 mg, Placebo, Comparator Agent	Zydus Therapeutics Inc.	Nonalcoholic Steatohepatitis, Fibrosis	09/25	09/25
ALTUS, NCT05064553: Performance of a Multi- Target Hepatocellular Carcinoma (HCC) Test in Subjects With Increased Risk	Recruiting	N/A	2500	US	Study CT/MRI Imaging, Standard of Care CT/MRI Imaging, Oncoguard™ Liver Test	Exact Sciences Corporation	Hepatocellular Carcinoma, Hepatocellular Cancer, Hepatitis B, Cirrhosis, Liver Cancer	06/25	12/26